期刊文献+

双侧原发性乳腺癌两癌间隔时间对ER PR HER-2表达一致性及预后的影响 被引量:9

Effects of the Time Interval between Bilateral Primary Breast Cancer on the Prognosis and Concordance of Hormone Receptor and Human Epidermal Growth Factor Receptor-2 Expression
下载PDF
导出
摘要 目的:分析两癌发生间隔时间对双侧原发性乳腺癌雌激素受体(ER)、孕激素受体(PR)及人表皮生长因子受体2(HER-2)表达一致性及预后的影响。方法:回顾性分析366例双侧原发性乳腺癌(bilateral primarv breast cancer,BPBC)患者的病理资料,按照两癌发生的间隔时间进行分组,侧重分析不同组内第一原发癌与第二原发癌ER、PR、HER-2表达的一致性及两癌间隔时间对BPBC预后的影响结果:BPBC第一原发癌与第二原发癌的ER、PR、HER-2表达呈正相关,两癌间隔时间≤12个月的BPBC双侧ER、PR、HER-2表达密切相关(P<0.05),而两癌间隔时间>12个月的BPBC双侧ER、PR、HER-2表达相关性无统计学意义(P>0.05)两癌间隔时间≤12个月较>12个月发生者远期生存率低,预后差结论:12个月内发生的BPBC两癌在ER、PR、HER-2表达方面具有较高的相似性,远期生存率较低,同异时性BPBC以12个月划分更能反映两癌之间的联系及预后。 Objective: To determine the effect of the time interval between bilateral primary breast cancer ( BPBC ) on the concordance of hormone receptor and human epidermal growth factor receptor ( HER )-2 expression and the prognosis. Methods: The medical records of 366 BPBC patients were reviewed, The patients were then grouped according to the time interval between the two cancers. Data analysis focused on the concordance of hormone receptor and HER-2 expression between the first and second primary breast cancers and the prognosis of BPBC in different groups. Results: There was a positive association between the hormone receptors and HER-2 of bilateral tumors. The strongest association was found in the group in which the time interval was ≤12 months ( P 〈 0.05 ). Although the concordance rate in the group with a time interval 〉12 months was high, there was no statistical significance ( P 〉 0.05 ). Patients with a time interval ≤ 12 months had lower overall survival rates than those with a time interval 〉12 months. Conclusion: The expression levels of estrogen receptor, progesterone receptor, and HER-2 in BPBC are greatly similar when the time interval is ≤ 12 months. Patients' overall survival rate is also lower when the time interval is 〉12 months. Synchronous and metachronous BP- BC divided by 12 months can reflect the association and prognosis of bilateral cancers.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2012年第11期777-780,共4页 Chinese Journal of Clinical Oncology
关键词 双侧原发性乳腺癌 雌激素受体 孕激素受体 人表皮生长因子受体2 Bilateral breast neoplasm Estrogen receptors Progesterone receptors HER-2
  • 相关文献

参考文献13

  • 1吕明丽,张晟,刘红,张瑾.双侧原发性乳腺癌ER、PR及HER-2表达特征及其与预后的关系[J].中华乳腺病杂志(电子版),2009,3(1):19-23. 被引量:18
  • 2Coradini D, Oriana S, Mariani L, et al. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corre- sponding primary tumour[J]. ? Eur J Cancer, 1998, 34(6): 825--830. 被引量:1
  • 3Gong SJ, Rha SY, Jeung HC, et al. Bilateral breast cancer: differential diagxlosis using histological and biological parameters[J]. Jpn j clin Oncol, 2007, 37(7): 487-492. 被引量:1
  • 4Huo D, Melkonian S, Rathouz PJ, et al. Concordance in histological and biological parameters between first and second primary breast cancers,[J]. Cancer, 2011, 117(5): 907-915. 被引量:1
  • 5Robbins GF, BergJW. Bilateral primary breast cancer: a prospective clinicopathological study[J]. Cancer, 1964, 17: 1501-1527. 被引量:1
  • 6阚秀编著..乳腺癌临床病理学[M],1993:314.
  • 7<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:165
  • 8Kollias J, Pinder SE, Denley HE, et al. Phenotypic similarities in bi- lateral breast cancer[J]. Breast Cancer Res Treat, 2004, 85 (3): 255-261. 被引量:1
  • 9Swain SM, WilsonJW, Mamounas EP, et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer[J].J Natl Cancer Inst, 2004, 96(7): 516-523. 被引量:1
  • 10Vuoto HD, Garcia AM, Candas GB, et al. Bilateral breast carcinoma: clinical characteristics and its impact on survival[J].Breast J, 2010, 16 (6): 625-632. 被引量:1

二级参考文献17

  • 1林燕,周易冬,孙强,黄汉源.原发性双侧乳腺癌[J].癌症进展,2005,3(3):207-211. 被引量:8
  • 2沈镇宙,韩企夏,庄传经,张广涵.双侧乳腺癌71例分析[J].上海医学,1989,12(5):252-255. 被引量:14
  • 3孙俊平,李碧丽,李毅平.原发性异时性双侧乳腺癌(附7例报告)[J].医师进修杂志,1994,17(11):29-30. 被引量:3
  • 4Watters AD,Going JJ,Cooke GT,et al.Chromosome 17 aneusomy is associated with poor prognostic factors in invesive breast carcinoma.Breast Cancer Res Treat,2003,77:109-114. 被引量:1
  • 5Bilous M,Morey A,Armes J,et al.Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.Pathology,2006,38:120-124. 被引量:1
  • 6Goldhirsch A,Glick JH,Gelber RD,et al.Meeting highlights:international expert consensus on the primary therapy of early breast cancer 2005.Annals Oncol,2005,16:1569-1583. 被引量:1
  • 7The Center For Devices and Radiological Health (CDRH) of the Food and Drug Administration.A document of evaluation about the PathVysionTM HER-2 DNA Probe Kit of Vysis,INC.for detecting amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed,paraffin-embedded human breast cancer tissue specimens.[2001-12-31].http://www.fda.gov/cdrh/pmapage.html. 被引量:1
  • 8Shak S.Overview of the trastuzumab (Hereeptin) anti-HER2monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer.Herceptin Multinational Investigator Study Group.Semin Oncol,1999,26(4 Suppl 12):71-77. 被引量:1
  • 9Hammock L,Lewis M,Philips,C,et al.Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.Hum Pathol,2003,34:1043-1047. 被引量:1
  • 10北京市发展和改革委员会.关于公布荧光原位杂交基因检测(FISH)等新增医疗服务价格项目的通知.京发改[2006]1376号.http://www.bjpc.gov.cn/tztg/200608/t129145.btm. 被引量:1

共引文献189

同被引文献59

引证文献9

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部